Genitope GTOP Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genitope GTOP

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: scaram(o)uche	10/9/2007 10:03:06 AM
	Read Replies (1) of 37

messages.finance.yahoo.com Reported on Briefing.com at 8:14... GTOP Genitope: Brean Murray believes Phase 3 MyVax trial will fail (3.56 ) Brean Murray notes GTOP is expected to report Phase 3 results from its MyVax trial in late Dec, and they strongly believe that the trial will fail and drive the co to a near-cash valuation; firm's year-end cash per share estimate is $0.75. They believe that if the Phase 3 MyVax trial fails at the end of the year, GTOP will have a very difficult time justifying optimism for the rest of its clinical and preclinical pipeline for additional fundraising. Firm believes its antibody panels are only commercially viable if MyVax receives approval. The greatest value firm sees in GTOP is the value of its net loss carry-forwards. Firm strongly recommends selling into such strength if it returns.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next